Results 111 to 120 of about 12,508,548 (262)

Partial FAK suppression promotes tumor growth, an effect reversed by macrophage p110δ PI3K inactivation

open access: yesMolecular Oncology, EarlyView.
Partial inhibition of focal adhesion kinase (FAK) can paradoxically promote tumor growth, rather than simply producing a weaker antitumor effect than that observed with strong FAK suppression. In breast cancer and melanoma models, targeting p110δ PI3K, particularly in macrophages, counteracted these tumor‐promoting effects, highlighting the importance ...
Lydia Xenou   +4 more
wiley   +1 more source

Mechanisms and therapeutic opportunities of the ribotoxic stress response in cancer

open access: yesMolecular Oncology, EarlyView.
Cancer cells' high translational demand creates opportunities to therapeutically target ribosome function. Ribosome stalling and collisions activate ZAKα and the ribotoxic stress response (RSR), which can trigger rapid, p53‐independent apoptosis in cancer.
Anastassiya Kim   +7 more
wiley   +1 more source

Predictive and prognostic biomarkers of Bacillus Calmette‐Guérin therapy failure in bladder cancer patients: A systematic review

open access: yesMolecular Oncology, EarlyView.
High‐risk bladder cancer is typically treated with Bacillus Calmette‐Guérin (BCG), but 30–40% of patients relapse. No FDA‐ or CE‐approved biomarkers currently predict or prognosticate BCG failure. We systematically reviewed the literature and identified 72 eligible studies, revealing several promising biomarkers associated with BCG treatment response ...
Rui Ribeiro‐Pereira   +7 more
wiley   +1 more source

Clinical laboratory COVID-19 response call : January 24, 2022

open access: yes
CDC\u2019s Division of Laboratory Systems (DLS) convenes regular calls with clinical laboratories to discuss the nation\u2019s clinical laboratory response to coronavirus disease (COVID-19).

core  

Bridging the gap: a genetically validated avian chorioallantoic membrane platform for investigation of spontaneous circulating tumor cells

open access: yesMolecular Oncology, EarlyView.
We established the avian chorioallantoic membrane (CAM) assay as a scalable in vivo model for studying circulating tumor cells (CTCs). Human gastrointestinal tumors spontaneously released genetically validated CTCs that were detected across multiple platforms, demonstrating that the CAM model provides an accessible tool for investigating early cancer ...
Dennis Roth   +17 more
wiley   +1 more source

Investigating interassay variability between direct oral anticoagulant calibrated anti–factor Xa assays: a substudy of the perioperative anticoagulation use for surgery evaluation (PAUSE) trial

open access: yesResearch and Practice in Thrombosis and Haemostasis
Background: Direct oral anticoagulant calibrated anti-factor Xa (FXa) assays can assess residual anticoagulant levels in patients requiring urgent procedures or surgery.
Ryan M. Baker   +6 more
doaj   +1 more source

The C‐terminal region of KIF26B is indispensable for nephron progenitor condensation and kidney formation in mice

open access: yesFEBS Open Bio, EarlyView.
KIF26B plays an important role in kidney development. We engineered mice lacking the C‐terminal region of KIF26B and found severe kidney defects, including bilateral renal agenesis, similar to full Kif26b knockout mice. The mutation disrupted nephron progenitor condensation and reduced Gdnf‐Wnt11 signaling, showing that the KIF26B C‐terminal region is ...
Yuta Yamamura   +19 more
wiley   +1 more source

Loss of AMBRA1 activates MAPK and angiogenesis signaling pathways in melanoma cells

open access: yesFEBS Open Bio, EarlyView.
Loss of AMBRA1 in melanoma cells activates multiple oncogenic pathways associated with tumor progression. Transcriptomic and protein network analyses revealed that AMBRA1 depletion enhances MAPK/ERK signaling, angiogenesis, TGF‐β/EMT signaling, and Wnt/axon guidance pathways.
Milad Ibrahim   +4 more
wiley   +1 more source

Clinical laboratory COVID-19 response call : May 16, 2022

open access: yes
CDC\u2019s Division of Laboratory Systems (DLS) convenes regular calls with clinical laboratories to discuss the nation\u2019s clinical laboratory response to coronavirus disease (COVID-19). These Clinical Laboratory COVID-19 Response Calls take place on

core  

Clinical laboratory COVID-19 response call : July 6, 2020 [PDF]

open access: yes
CDC\u2019s Division of Laboratory Systems (DLS) convenes regular calls with clinical laboratories to discuss the nation\u2019s clinical laboratory response to coronavirus disease (COVID-19).

core  

Home - About - Disclaimer - Privacy